Outcomes | DG (n = 12) | WG (n = 6) | P |
---|---|---|---|
Age | 68.6 ± 6.7 [64.3–72.8] a | 64.2 ± 4.9 [59.0–69.3] a | 0.174 |
Body Mass (kg) | 75.2 ± 11.3 [68–82.3] a | 75.2 ± 13.2 [61.3–89] a | 1.000 |
Height (m) | 1.60 ± 0.08 [1.55–1.65] a | 1.64 ± 0.05 [1.59–1.69] a | 0.266 |
Diagnosis Time Disease | 3.5 ± 1.3 [2–7.8] b | 5.5 ± 2.2 [1.9–13.1] b | 0.151 |
H&Y | 1.5 ± 0.2 [1.3–2.4] b | 2.5 ± 0.3 [1.5–3.1] b | 0.180 |
TUG SSS (s) | 11.7 ± 2.5 [10.1–13.3] a | 11.2 ± 1.7 [9.4–13] a | 0.677 |
TUG FS (s) | 9.3 ± 0.6 [8.2–10.7] b | 9.3 ± 0.4 [8.2–10.4] b | 0.820 |
UPDRS III | 13.5 ± 7.4 [8.8–18.2] a | 23.8 ± 8.2 [15.2–32.5] a | 0.016* |
SSS (m/s) | 1.02 ± 0.2 [0.9–1.1] a | 1.08 ± 0.2 [0.9–1.3] a | 0.464 |
Sex | 9 women / 3 men | 2 women / 4 men | NA |
Clinical Symptoms | |||
ȀInstability / lack of balance | 8 (66.6%) | 4 (66.6%) | NA |
Tremor | 10 (83.3%) | 5 (83.3%) | NA |
Postural change | 2 (16.6%) | 1 (16.6%) | NA |
Rigidity | 9 (75%) | 5 (83.3%) | NA |
Bradykinesia | 12 (100%) | 6 (100%) | NA |
Dyskinesia | 2 (16.6%) | 1 (16.6%) | NA |
Falls History | 6 (50%) | 3 (50%) | NA |
DP specific medication | |||
Levodopa – Cardidopa | 2 (16.6%) | 0 (0%) | NA |
daily dose (mg) | 1650 (1200–2100) | 0 (0–0) | NA |
Prolopa | 10 (83.3%) | 6 (100%) | NA |
daily dose (mg) | 585 (250–1000) | 545 (188–1000) | NA |
Physical Exercise Practice | 8 (66.6%) | 4 (66.6%) | NA |